Key result
Combined heart-liver transplantation successfully treats end-stage iron overload from homozygous beta-thalassemia.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Most patients with homozygous β-thalassemia require red-cell transfusions to survive beyond the first decade of life. Although this intervention clearly prolongs survival,1 it also results in the accumulation of iron in tissue, which is itself fatal without iron-chelating therapy2. Before the introduction of deferoxamine, iron-induced cardiac dysfunction was a predictable outcome in thalassemia,3 and it is still the leading cause of death, followed in incidence by hepatic disease1. Despite the successes with deferoxamine,4–7 many patients still have serious complications, because of either advanced age at the start of therapy or erratic compliance8–14. To date, the . . .
No takes yet. Share an insight, caveat, or question.
Olivieri et al. (1994) conducted a case report in Homozygous beta-thalassemia with end-stage iron-induced cardiac and hepatic organ failure (n=1). Combined liver and heart transplantation was evaluated. Combined liver and heart transplantation was performed in 1 adult patient for end-stage iron-induced organ failure in homozygous beta-thalassemia.
Synapse has enriched 10 related papers. Consider them for comparative context: